### A Deeptech Startup in Biotech and Healthcare



# "A Metabolic 3D Healthcare System for Diabetes"

- Artificial Pancreas(Closed-Loop);
  - Continuous Glucose Monitoring(CGM),
  - Automatic Insulin Pump, and
  - NoType.Al Insulin Auto-delivery System
- Connected Healthcare Mobile Application

# Problems of Diabetics

- Pain & Uncomfort; finger pricks and insulin injections
- **Self-care**; Children need assistance
- Accessibility
- Affordability
- Nutrition and Diet
- Physical Body health

# **Statistics**

537 million

adults are living with diabetes

6.7 million

deaths in 2021 due to diabetes

966
billion (USD)

health expenditure caused by diabetes


# Solution - A Metabolic 3D Healthcare (Monitoring & Management)

A more effective and affordable solution **Diabetes Type 1 and 2**.

A Sweet Spot in Turkic States, MENA and North America.


Smart Continuous 3D Monitoring:		Smart (3D) Management:		
1.	Glucose level & health vitals	———1.	Insulin auto-delivery system	
2.	Nutrition; food & carbs		Personalized <b>Diet</b> program	
3.	Physical health & fitness	→ 3.	Personalized Workout program	

# <u>Medixbot Products – Full-stack Components (Prototype/MVP)</u>




### <u>Products – Medical Devices</u>

#### **Continuous Glucose Monitoring(CGM)-Prototype**








### **Working Prototype:**

- 4x16 arrays of microneedles
- PCB Circuit
- Embedded Algorithm
- Embedded Al




#### Artificial Pancreas (Closed-Loop) - In dev.



# Prototype under development:

- Built-in CGM
- Insulin Auto-Pump
- Embedded Al
- Embedded Algorithm





### **Our Team**

#### **Founding and Management Team**

MSc in AI, BSc in CS



Jonathan Makomo,
CTO, Medixbot
MSc Mechatronics



Prof.Dr. Mustafa Can
Biomed and chemical Eng., Univ.,
Sakarya Biomed Advisor



Sami Hamdan Al-Saedi, MD Medical Devices Advisor, BSc. Medicine



Prof.Dr. Gülnur ARABACI
Chemistry/Biotech Eng. SK
Univ., Chemistry/Biotech Advisor

Ali Lazim, CEO and Founder

Cofounder of SAASPASS(exit)



James Nyamhondoro, MD Healthcare Advisor, Chronic Diseases expert



Nur Lazim,
Team Leader, Medixbot
BSc Dietetics



Prof.Dr. Mustafa Zahid YILDIZ

Mechatronic Eng., SK Univ.,

Mechatronic/Biomed Advisor




John A. Mauldin, Business Dev. Manager, BSc. in Business, Biz Dev Manager, SAASPASS


- **3** Offices
- 4 Labs
- **37** Team member

- 4 Executives
- 4 Prof. Researchers
- 2 Medical Experts

- 4 Mechatronic, Mechanical, & Embedded Systems
- **3** Biochemical and Material Engineering
- 4 Biomedical Engineering
- 6 AI/ML and Data Science
- **8** Software Engineering, and DevOps
- **3** Concept/Product Design and 3D Design



# **Market Size**



#### Market In Numbers:

- Abbott Laboratories & Dexcom are the leaders in the CGM market, which hit \$5.1 billion in revenue in 2021. Projected \$13.2 billion by 2028. (Ref)
- The Global Insulin Pump Market is valued at USD 4.20 billion in 2021. Projected USD 10.18 billion by 2028 at a CAGR of 15.90%. (Ref)

# Competitive Landscape - CGM & Insulin Pump

CGM/Insulin Pump Features	Abbott	Dexcom	Medtronic	Medixbot
Full-stack Closed Loop Artificial Pancreas (CGM + Insulin Pump)	No	No	No	Yes
Microneedles(MN)	One Long MN	One Long MN	One Long MN	Array of MNs
Sensor life	14 days	10 days	7 days	14 days
Decision support AI	No	No	Yes	Yes
Warm up period	12 hours	2 hours	2 hours	1 hours
Alarms/Alerts	Yes	Yes	Yes	Yes
Tubing-free and Detachable Patch Pump	No	No	No	Yes
Reusable Transmitter	No	Yes	Yes	Yes
Need Reader to carry	Yes	Yes	Yes	No
Reusable applicator	No	No	No	Automatic built-in mechanism
Continuous subcutaneous insulin infusion (CSII)	No	No	No	Yes
Waterproof IPX8 and high Thermal insulator	No	No	No	Yes
Sensor calibration	Factory	Factory	2x/day	Factory
MARD Accuracy	8%	9-10%	10%	<8%
Cost	\$1780/yr	\$3630/yr	\$3950/yr	\$780/yr
"Automatic Insulin Bump"	No	No	Yes	Yes
Automatic Insulin Delivery system	No	Yes	No	Yes
FDA's iCGM Compatibility	Yes	Yes	Yes	Yes

## Competitive Advantages and Current Status Demo

- One smart wearable device; CGM & Insulin Pump(competitors' DIY)
- <u>Full-stack</u> Autonomous and Personalized healthcare for diabetes
- Microneedles technology and lightweight miniaturized devices
- Built-in; Insulin auto-delivery, Diet, Workout, Telemedicine & Engagement
- <u>Cheaper & Greener</u> (only MNs need to be replaced)
- Logistic & tax advantages in Turkic States & Middle East with 2 LOIs
- A ready grant of \$300K for building a factory in Turkey
- Low User Acquisitions
- To be a **MONOPOLY** with a sustainable growth in Turkic States and MENA









Demo on YouTube – Click to watch

https://youtu.be/aClpZhE\_RJE

### **Business Model**

- First, our mobile and smartwatch apps will be integrated with the 3rd parties' devices.
- Second, our own device will be released upon approval.

B<sub>2</sub>C

- Direct online sales
- Premium users; subscribers
- Family memberships
- Subscriptions to food management and fitness separately

B2B2C

- Insurance companies
- Global network of distributors
- Healthcare institutions

B2G

- Government Healthcare National Insurance Programs
- Government Supply Companies

### Medixbot R&D: CareBot

### A Nanorobotics/Moving Telerobotics in Medicine

- A Nanorobotics Capsule: to be swallow and works in the Stomach(Gastroenterology)
- Enzyme Coated Micro Capsule
- With a storage for Drug delivery
- Components: Silicone case, microcontroller, Al control
- Functions: Measurement, monitoring, treatments, drug release
- Moving Telerobotics: Autonomous movement with propellers
- Vision: Shrinking for blood vessel use


**Application:** Utilizing it for Blood Glucose Level Estimation through Stomach and Intestinal Metabolism using Ghrelin as biomarker.





# **Projections**

\*\*\* Two LOIs from the Ministry of Health in Turkey and Iraq.



Projected
3rd year 2025
Revenue
\$75M

**Expanding to North American markets:** 

- FDA Approval
- VIATEC

BOOTSTRAP \$200K

> F&F \$250K

GRANT \$50K KOSGEB

VIATEC Accelerator

## **Seeking investment**

\$2M

+\$300K Gov. Match (of \$300K from us)

• CE Mark

- Scaling Manufacturing
- Operation
- Marketing and Distribution

